

Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis

NCT07187661

Status	RECRUITING
Phase	Not Applicable
Sponsor	Khyber Medical University Peshawar
Enrollment	25 participants

Key Eligibility Criteria

Inclusion (5)

- Confirmed diagnosis of Hemophilia A.
- Presence of one or more target joints (knee, elbow, ankle) with chronic synovitis and a history of ≥ 2 hemarthrosis episodes in the past 6 months.
- Target joint World Federation of Hemophilia (WFH) joint score of 2-3.
- Adequate hematological, renal, and liver function (as specified by protocol lab values).
- Ability and willingness to provide informed consent and comply with the study protocol.

Exclusion (6)

- HIV positive diagnosis.
- Severely damaged joints or anatomical limitations preventing safe injection.
- Contraindications to MRI.
- Uncontrolled hypertension.
- Recent major surgery/trauma (≤ 28 days).

... and 1 more (see full listing online)

Locations (2 total)

Hayatabad Medical Complex, Peshawar, KPK, Pakistan
Institute of Pathology and Diagnostic Medicine (IPDM), Peshawar, KPK, Pakistan